Manipulating Cardiac Contractility in Heart Failure: Data from Mice and Men

Circulation

Volumn 109, Issue 2, 2004, Pages 150-158

  Dorn II, Gerald W ^a   Molkentin, Jeffery D ^a,b  

^a CINCINNATI CHILDREN'S HOSPITAL MEDICAL CENTER   (United States)

^b UNIVERSITY OF CINCINNATI MEDICAL CENTER   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

BETA 1 ADRENERGIC RECEPTOR; BETA 1 ADRENERGIC RECEPTOR STIMULATING AGENT; BETA 2 ADRENERGIC RECEPTOR; BETA ADRENERGIC RECEPTOR; BETA ADRENERGIC RECEPTOR BLOCKING AGENT; BRAIN NATRIURETIC PEPTIDE; CYCLIC AMP RESPONSIVE ELEMENT BINDING PROTEIN BINDING PROTEIN; DIPEPTIDYL CARBOXYPEPTIDASE INHIBITOR; DOBUTAMINE; INOTROPIC AGENT; LEVOSIMENDAN; MILRINONE; NESIRITIDE; PHOSPHODIESTERASE INHIBITOR; PHOSPHOLAMBAN; PIPERANOMETOZINE; PROTEIN; PROTEIN SERCA2; UNCLASSIFIED DRUG;

BETA ADRENERGIC STIMULATION; CARDIOVASCULAR DISEASE; CLINICAL TRIAL; DRUG EFFICACY; HEART FAILURE; HEART MUSCLE; HEART MUSCLE CONTRACTILITY; HUMAN; MOUSE; NONHUMAN; PRIORITY JOURNAL; PROTEIN FUNCTION; PROTEIN PHOSPHORYLATION; PROTEIN PROTEIN INTERACTION; RECEPTOR DOWN REGULATION; REVIEW; SIGNAL TRANSDUCTION; TREATMENT OUTCOME;

ANIMALS; CALCIUM-BINDING PROTEINS; CALCIUM-TRANSPORTING ATPASES; CARDIAC OUTPUT, LOW; CARDIOTONIC AGENTS; DISEASE MODELS, ANIMAL; HUMANS; MICE; MYOCARDIAL CONTRACTION; MYOCARDIUM; RECEPTORS, ADRENERGIC, BETA; SARCOPLASMIC RETICULUM CALCIUM-TRANSPORTING ATPASES; SIGNAL TRANSDUCTION; SPECIES SPECIFICITY;

EID: 1642576183     PISSN: 00097322     EISSN: None     Source Type: Journal    
DOI: 10.1161/01.CIR.0000111581.15521.F5     Document Type: Review

References (83)

1. Pearson TA. Cardiovascular disease in developing countries: myths, realities, and opportunities. Cardiovasc Drugs Ther. 1999;13:95-104.
2. Murray CJL, Lopez AD. The Global Burden of Disease: A Comprehensive Assessment of Mortality and Disability from Diseases, Injuries, and Risk Factors in 1990 and Projected to 2020. Cambridge, Mass: Harvard University Press; 1996.
3. Kannel WB. Overview of atherosclerosis. Clin Ther. 1998:20(suppl B):B2-B17.
4. Lloyd-Jones DM, Larson MG, Leip EP, et al. Lifetime risk for developing congestive heart failure: the Framingham Heart Study. Circulation. 2002;106:3068-3072.
5. American Heart Association. 1998. Heart and Stroke Statistical Update. Dallas, Tex: American Heart Association, 1997.
6. Adams KF Jr. New epidemiologic perspectives concerning mild-to-moderate heart failure. Am J Med. 2001;110(suppl 7A):6S-13S.
7. Remme WJ. Positive inotropes: a new horizon or still a dead end? Cardiovasc Drugs Ther. 2001;15:375-377.
8. Felker GM, O'Connor CM. Inotropic therapy for heart failure: an evidence-based approach. Am Heart J. 2001;142:393-401.
9. Packer M. Current role of β-adrenergic blockers in the management of chronic heart failure. Am. J. Med. 2001;110(suppl 7A):81S-94S
10. Bristow MR. β-Adrenergic receptor blockade in chronic heart failure. Circulation. 2000;101:558-569.
11. Bouzamondo A, Hulot JS, Sanchez P, et al. β-Blocker treatment in heart failure. Fundam Clin Pharmacol. 2001;15:95-109.
12. Liggett SB. β-Adrenergic receptors in the failing heart: the good, the bad, and the unknown. J Clin Invest. 2001;107:947-948.
13. Port JD, Bristow MR. Altered β-adrenergic receptor gene regulation and signaling in chronic heart failure. J Mol Cell Cardiol. 2001;33:887-905.
14. Yatani A, Brown AM. Rapid β-adrenergic modulation of cardiac calcium channel currents by a fast G protein pathway. Science. 1989;245:71-74.
15. Lader AS, Xiao YF, Ishikawa Y, et al. Cardiac Gsa overexpression enhances L-type calcium channels through an adenylyl cyclase independent pathway. Proc Natl Acad Sci U S A. 1998;95:9669-9674.
16. Schmidt AG, Edes I, Kranias EG. Phospholamban: a promising therapeutic target in heart failure? Cardiovasc Drugs Ther. 2001;15:387-396.
17. Kentish JC McCloskey DT, Layland J, et al Phosphorylation of troponin I by protein kinase A accelerates relaxation and crossbridge cycle kinetics in mouse ventricular muscle. Circ Res. 2001;88:1059-1065.
18. Pitcher JA, Freedman NJ, Lefkowitz RJ. G protein-coupled receptor kinases. Annu Rev Biochem. 1998;67;653-692.
19. Iaccarino G, Tomhave ED, Lefkowitz RJ, et al. Reciprocal in vivo regulation of myocardial G protein-coupled receptor kinase expression by β-adrenergic receptor stimulation and blockade. Circulation. 1998;98:1783-1789.
20. Choi DJ, Koch WJ, Hunter JJ, et al. Mechanism of β-adrenergic receptor desensitization in cardiac hypertrophy is increased β-adrenergi receptor kinase. J Biol Chem. 1997;272:17223-17229.
21. Koch WJ, Rockman HA, Samama P, et al. Cardiac function in mice overexpressing the β-adrenergiic receptor kinase or a βARK inhibitor. Science. 1995;268:1350-1353.
22. Molkentin JD, Doro II GW 2nd. Cytoplasmic signaling pathways that regulate cardiac hypertrophy. Annu Rev Physiol. 2001;63:391-426.
23. 2-adrenergic receptor to different G proteins by protein kinase A. Nature. 1997;390:88-91.
24. 2-adrenoceptors in neonatal cardiac myocytes. J Biol Chem. 2002;277:34280-34286.
25. Rybin VO, Xu X, Lisanti MP, et al. Differential targeting of β-adrenergic receptor subtypes and adenylyl cyclase to cardiomyocyte caveolae. A mechanism to functionally regulate the cAMP signaling pathway. J Biol Chem. 2000;275:41447-41457.
26. Steinberg SF. The cellular actions of β-adrenergic receptor agonists: looking beyond cAMP. Circ Res. 2000;87:1079-1082.
27. 2-adrenergic receptor. Science. 1994;264:582-586.
28. Liggett SB, Tepe NM, Lorenz JN, et al. Early and delayed consequences of β(2)-adrenergic receptor overexpression in mouse hearts: critical role for expression level. Circulation. 2000;101:1707-1714.
29. 2-adrenergic receptor transgenic mice. Proc Natl Acad Sci USA. 1999;96:7059-7064.
30. 2 receptors differentially affect cardiac hypertrophy and function in Gαq-overexpressing mice. Proc Natl Acad Sci USA. 1999;96:6400-6405.
31. Rockman HA, Chien KR, Choi DJ, et al. Expression of a β-adrenergic receptor kinase 1 inhibitor prevents the development of myocardial failure in gene-targeted mice. Proc Natl Acad Sci USA. 1998;95:7000-7005.
32. Harding VB, Jones LR, Lefkowitz RJ, et al. Cardiac βARK1 inhibition prolongs survival and augments β blocker therapy in a mouse model of severe heart failure. Proc Natl Acad Sci USA. 2001;98:5809-5814.
33. Freeman K, Lerman I, Kranias EG, et al. Alterations in cardiac adrenergic signaling and calcium cycling differentially affect the progression of cardiomyopathy. J Clin Invest. 2001;107:967-974.
34. White DC, Hata JA, Shah AS, et al. Preservation of myocardial β-adrenergic receptor signaling delays the development of heart failure after myocardial infarction. Proc Natl Acad Sci USA. 2000;97:5428-5433.
35. Shah AS, White DC, Emani S, et al. In vivo ventricular gene delivery of a β-adrenergic receptor kinase inhibitor to the failing heart reverses cardiac dysfunction. Circulation. 2001;103:1311-1316.
36. Eckhart AD, Fentzke RC, Lepore J, et al. Inhibition of βARK1 restores impaired biochemical β-adrenergic receptor responsiveness but does not rescue CREB(A133) induced cardiomyopathy. J Mol Cell Cardiol. 2002;34:669-677.
37. Cross HR, Steenbergen C, Lefkowitz RJ, et al. Overexpression of the cardiac β(2)-adrenergic receptor and expression of a β-adrenergic receptor kinase-1 (βARK1) inhibitor both increase myocardial contractility but have differential effects on susceptibility to ischemic injury. Circ Res. 1999;85:1077-1084.
38. Du XJ, Autelitano DJ, Dilley RJ, et al. β(2)-Adrenergic receptor overexpression exacerbates development of heart failure after aortic stenosis. Circulation. 2000;101:71-77.
39. Iwase M, Bishop SP, Uechi M, et al. Adverse effects of chronic endogenous sympathetic drive induced by cardiac GSα overexpression. Circ Res. 1996;78:517-524.
40. Iwase M, Uechi M, Vatner DE, et al. Cardiomyopathy induced by cardiac Gsα overexpression. Am J Physiol. 1997;272:H585-H589.
41. 2+ cycling proteins and the action potential in heart failure by gene transfer. Basic Res Cardiol. 2002;97(suppl I):I-136-1-145.
42. Bers DM. Cardiac excitation-contraction coupling. Nature. 2002;415:198-205.
43. Haghighi K, Kolokathis F, Pater L, et al. Human phospholamban null results in lethal dilated cardiomyopathy revealing a critical difference between mouse and human. J Clin Invest. 2003;111:869-876.
44. Harding VB, Jones LR, Lefkowitz RJ, et al. Cardiac βARK1 inhibition prolongs survival and augments β blocker therapy in a mouse model of severe heart failure. Proc Natl Acad Sci U S A. 2001;98:5809-5814.
45. Asai K, Yang GP, Geng YJ, et al. β-Adrenergic receptor blockade arrests myocyte damage and preserves cardiac function in the transgenic G(sα) mouse. J Clin Invest. 1999;104:551-558.
46. Margulies KB. Reversal mechanisms of left ventricular remodeling: lessons from left ventricular assist device experiments. J Card Fail. 2002;8:S500-S505.
47. Esposito G, Rapacciuolo A, Naga Prasad SV, et al. Genetic alterations that inhibit in vivo pressure-overload hypertrophy prevent cardiac dysfunction despite increased wall stress. Circulation. 2002;105:85-92.
48. Rapacciuolo A, Esposito G, Caron K, et al. Important role of endogenous norepinephrine and epinephrine in the development of in vivo pressure-overload cardiac hypertrophy. J Am Coll Cardiol. 2001;38:876-882.
49. Luo W, Grupp IL, Harrer J, et al. Targeted ablation of the phospholamban gene is associated with markedly enhanced myocardial contractility and loss of β-agonist stimulation. Circ Res. 1994;75:401-409.
50. 2+ ATPase gene in the heart of transgenic mice accelerates calcium transients and cardiac relaxation. J Clin Invest. 1997;100:380-389.
51. Greene AL, Lalli MJ, Ji Y, et al. Overexpression of SERCA2b in the heart leads to an increase in sarcoplasmic reticulum calcium transport function and increased cardiac contractility. J Biol Chem. 2000;275:24722-24727.
52. Minamisawa S, Hoshijima M, Chu G, et al. Chronic phospholamban-sarcoplasmic reticulum calcium ATPase interaction is the critical calcium cycling defect in dilated cardiomyopathy. Cell. 1999;99:313-322.
53. Sato Y, Kiriazis H, Yatani A, et al. Rescue of contractile parameters and myocyte hypertrophy in calsequestrin overexpressing myocardium by phospholamban ablation. J Biol Chem. 2001;276:9392-9399.
54. Hoshijima M, Ikeda Y, Iwanaga Y, et al. Chronic suppression of heart-failure progression by a pseudophosphorylated mutant of phospholamban via in vivo cardiac rAAV gene delivery. Nat Med. 2002;8:864-871.
55. Trost SU, Belke DD, Bluhm WF, et al. Overexpression of the sarcoplasmic reticulum Ca(2+)-ATPase improves myocardial contractility in diabetic cardiomyopathy. Diabetes. 2002;51:1166-1171.
56. 2+ affinity mutant of SERCA2a attenuates in vivo pressure overload cardiac hypertrophy. FASEB J. 2003;17:61-63.
57. del Monte F, Harding SE, Schmidt U, et al. Restoration of contractile function in isolated cardiomyocytes from failing human hearts by gene transfer of SERCA2a. Circulation. 1999;100:2308-2311.
58. del Monte F, Harding SE, Dec GW, et al. Targeting phospholamban by gene transfer in human heart failure. Circulation. 2002;105:904-907.
59. Miyamoto MI, del Monte F, Schmidt U, et al. Adenoviral gene transfer of SERCA2a improves left-ventricular function in aortic-banded rats in transition to heart failure. Proc Natl Acad Sci U S A. 2000;97:793-798.
60. del Monte F, Williams E, Lebeche D, et al. Improvement in survival and cardiac metabolism after gene transfer of sarcoplasmic reticulum Ca(2+)-ATPase in a rat model of heart failure. Circulation. 2001;104:1424-1429.
61. Haghighi K, Schmidt AG, Hoit BD, et al. Superinhibition of sarcoplasmic reticulum function by phospholamban induces cardiac contractile failure. J Biol Chem. 2001;276:24145-24152.
62. Schmitt JP, Kamisago M, Asahi M, et al. Dilated cardiomyopathy and heart failure caused by a mutation in phospholamban. Science. 2003;299:1410-1413.
63. Delling U, Sussman MA, Molkentin JD. Re-evaluating sarcoplasmic reticulum function in heart failure. Nat Med. 2000;6:942-943.
64. Song Q, Schmidt AG, Hahn HS, et al. Rescue of cardiomyocyte dysfunction by phospholamban ablation does not prevent ventricular failure in genetic hypertrophy J Clin Invest. 2003;111:859-867.
65. Francis GS, Tang WH. Pathophysiology of congestive heart failure. Rev Cardiovasc Med. 2003;4:S14-S20.
66. Houser SR, Margulies KB. Is depressed myocyte contractility centrally involved in heart failure? Circ Res. 2003;92:350-358.
67. Colucci WS, Leatherman GF, Ludmer PL, et al. β-Adrenergic inotropic responsiveness of patients with heart failure: studies with intracoronary dobutamine infusion. Circ Res. 1987;61(suppl I):I-82-I-86.
68. Feldman AM, Bristow MR, Parmley WW, et al. Effects of vesnarinone on morbidity and mortality in patients with heart failure. Vesnarinone Study Group. N Engl J Med. 1993;329:149-155.
69. Chatterjee K, De Marco T. Role of nonglycosidic inotropic agents: indications, ethics, and limitations. Med Clin North Am. 2003;87:391-418.
70. Warner-Stevenson L. Clinical use of inotropic therapy for heart failure: looking backward or forward? Circulation. 2003;108:492-497.
71. Leier CV, Binkley PF. Parenteral inotropic support for advanced congestive heart failure. Prog Cardiovasc Dis. 1998;41:207-224.
72. Kazanegra R, Cheng V, Garcia A, et al. A rapid test for B-type natriuretic peptide correlates with falling wedge pressures in patients treated for decompensated heart failure: a pilot study. J Card Fail. 2001;7:21-29.
73. Harrison A, Morrison LK, Krishnaswamy P, et al. B-type natriuretic peptide predicts future cardiac events in patients presenting to the emergency department with dyspnea. Ann Emerg Med. 2002;39:131-138.
74. Marcus LS, Hart D, Packer M, et al. Hemodynamic and renal excretory effects of human brain natriuretic peptide infusion in patients with congestive heart failure: a double-blind, placebo-controlled, randomized crossover trial. Circulation. 1996;94:3184-3189.
75. Colucci WS, Elkayam U, Horton DP, et al. Intravenous nesiritide, a natriuretic peptide, in the treatment of decompensated congestive heart failure. Nesiritide Study Group. N Engl J Med. 2000;343:246-253.
76. Burger AJ, Horton DP, LeJemtel T, et al. Effect of nesiritide (B-type natriuretic peptide) and dobutamine on ventricular arrhythmias in the treatment of patients with acutely decompensated congestive heart failure: the PRECEDENT study. Am Heart J. 2002;144:1102-1108.
77. Dipla K, Mattiello JA, Jeevanandam V, et al. Myocyte recovery after mechanical circulatory support in humans with end-stage heart failure. Circulation. 1998;97:2316-2322.
78. Packer M, Gheorghiade M, Young JB, et al. Withdrawal of digoxin from patients with chronic heart failure treated with angiotensin-converting-enzyme inhibitors. RADIANCE Study. N Engl J Med. 1993;329:1-7.
79. Garg R, Gorlin R, Smith T, et al. The effect of digoxin on mortality and morbidity in patients with heart failure. The Digitalis Investigation Group. N Engl J Med. 1993;336:525-533.
80. 2+ sensitivity of cardiac myofibrils and sarcoplasmic reticulum in guinea pig heart. Circ Res. 1995;77:107-113.
81. Hasenfuss G, Pieske B, Castell M, et al. Influence of the novel inotropic agent levosimendan on isometric tension and calcium cycling in failing human myocardium. Circulation. 1998;98:2141-2147.
82. Slawsky MT, Colucci WS, Gottlieb SS, et al. Acute hemodynamic and clinical effects of levosimendan in patients with severe heart failure. Study Investigators. Circulation. 2000;102:2222-2227.
83. Packer M, Nienimen MS, Hasefuss G. Effects if intravenous levosimendan, a calcium sensitizer, on the survival of hospitalized patients with heart failure. Circulation 1999;100(suppl I):I-646.